Company / R&D per Share
Foghorn Therapeutics Inc. R&D per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.70
FY2025
5-year range
$1.57 / $2.59
FY2021-FY2025
Trend
-34.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2.53 to $1.70 over the past 2 years.
Based on SEC 10-K filings.
1.70 in FY2025 with a 5-year CAGR of -28.5%.
Declined from $2.53 to $1.70 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -4.4%
- 5-Year CAGR
- -28.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 34.5% year-over-year.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.70 | -34.5% |
| FY2024 | $2.59 | +2.7% |
| FY2023 | $2.53 | +29.9% |
| FY2022 | $1.94 | +24.0% |
| FY2021 | $1.57 | -82.8% |
| FY2020 | $9.11 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026